Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for ...
MedPage Today on MSN
Myasthenia gravis gets a new drug approval
In recent years, five other drugs have been approved to treat gMG, including three complement inhibitors -- eculizumab ...
Inebilizumab-cdon is approved for anti-acetylcholine receptor and anti-muscle specific tyrosine kinase antibody–positive generalized myasthenia gravis, based on MINT trial results. Inebilizumab gains ...
Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...
Zacks Investment Research on MSN
Here's how AMGN benefits from FDA nod to Uplizna in myasthenia gravis
Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication — ...
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who ...
(MENAFN- GlobeNewsWire - Nasdaq) Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK antibody-positive In the ...
Nicholas J. Silvestri, MD, expects that the upcoming 2025 American Academy of Neurology Annual Meeting in San Diego will be an exciting event for the field of myasthenia gravis (MG), with anticipated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results